Cite
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
MLA
St Jean, Pamela L., et al. “Tafenoquine Treatment of Plasmodium Vivax Malaria: Suggestive Evidence That CYP2D6 Reduced Metabolism Is Not Associated with Relapse in the Phase 2b DETECTIVE Trial.” Malaria Journal, vol. 15, Feb. 2016, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12936-016-1145-5.
APA
St Jean, P. L., Zhengyu Xue, Carter, N., Koh, G. C. K. W., Duparc, S., Taylor, M., Beaumont, C., Llanos-Cuentas, A., Rueangweerayut, R., Krudsood, S., Green, J. A., & Rubio, J. P. (2016). Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malaria Journal, 15, 1–9. https://doi.org/10.1186/s12936-016-1145-5
Chicago
St Jean, Pamela L., Zhengyu Xue, Nick Carter, Gavin C. K. W. Koh, Stephan Duparc, Maxine Taylor, Claire Beaumont, et al. 2016. “Tafenoquine Treatment of Plasmodium Vivax Malaria: Suggestive Evidence That CYP2D6 Reduced Metabolism Is Not Associated with Relapse in the Phase 2b DETECTIVE Trial.” Malaria Journal 15 (February): 1–9. doi:10.1186/s12936-016-1145-5.